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Abstract
Background: The purpose of this study was to determine the risk factors for and incidence as well as prognostic
impact of pathologic fracture (PF) and metastatic spinal cord compression (MSCC) in patients with bone
metastases (BM) from prostate cancer.
Methods: Retrospective cohort study including 61 consecutive patients seen at Nordland hospital’s department of
oncology between 2007 and 2009. The initial diagnosis of BM might have been made earlier. Twenty-nine patients
(48%) received taxotere and 72% zoledronic acid after diagnosis of BM.
Results: Median actuarial survival after diagnosis of BM was 23 months. Six patients (10%) were alive at 5 years.
Bone pain at baseline was present in 49% of patients. Eighty-nine percent required external beam radiotherapy
and/or radioisotopes after diagnosis of BM. Seventeen patients (28%) developed at least one major skeletal
complication, i.e. MSCC or PF (4 of them developed more than one). The actuarial risk was 44% at 4 and 5 years.
Most events developed before treatment with zoledronic acid and/or taxotere. Median survival from diagnosis of
either MSCC or PF was 11 months (5 months from MSCC). We did not identify statistically significant risk factors for
development of major skeletal complications. Serum alkaline phosphatase above median value and age less than
or equal to 70 years were the only risk factors approaching significance.
Conclusions: We found high rates of major skeletal complications in this unselected contemporary group of
patients. Identification of risk factors might guide the development of early interventions aiming at prevention of
MSCC and PF.
Background
Bone metastasis is a common complication in patients
with advanced stage prostate cancer and might even be
found already at first clinical diagnosis [1,2]. Increasing
extent of spread might compromise bone stability,
resulting in pathologic facture (PF) [3]. In addition, at
least 5-10% of patients might develop metastatic spinal
cord compression (MSCC) with or without vertebral
fracture [4]. Prognosis after onset of MSCC is limited.
Factors predicting for these two major skeletal compli-
cations in patients managed by practitioners outside of
prospective clinical trials are not completely understood.
To study the incidence, outcome and risk factors for PF
and MSCC in men with prostate cancer and skeletal
metastases, a retrospective cohort study was performed.
Methods
A retrospective analysis, which included all patients
with prostate cancer and bone metastases treated at
the authors’ institution during 2007, 2008 and early
2009 was performed. The authors’ institution is a com-
munity hospital in rural Norway, which is the only
oncology care provider and services the complete
population of the county, i.e. approximately 236,000
inhabitants. Thus, the 61 consecutive patients included
in this study represent an unselected population. Fol-
low-up information was available in all patients. The
initial diagnosis of bone metastases might have been
made before 2007. Our laboratory provided the follow-
ing information on normal ranges: haemoglobin (Hb)
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U/L, serum lactate dehydrogenase (LDH) <205 U/L
and serum calcium 2.15-2.55 mmol/L. We used the
Kaplan-Meier method to generate actuarial survival
curves. Patients without event were censored at last
clinical follow-up. Survival was calculated from the
date of imaging diagnosis of bone metastases (typically
by isotope bone scan) or from development of other
analysed events. Survival curves were compared with
the log rank test. Afterwards, statistically significant
prognostic factors for survival were examined by multi-
variate Cox regression analysis (forward stepwise data
selection method). Wilcoxon- and Kruskal-Wallis-tests
were used to compare the baseline characteristics
between different groups. Risk factors for development
of PF and MSCC were evaluated with the Fisher exact
test and confirmed by actuarial Kaplan-Meier analyses
as these were time-dependent events. PF was defined
a sab o n eb r o k e n ,n o tb yt r a u m aa l o n e ,b u ts ow e a -
kened by metastatic spread as to break with abnormal
ease [5,6]. MSCC was defined as compression by direct
pressure and/or induction of vertebral collapse or
instability by metastatic spread that threatens or causes
neurological disability [5,6]. Vertebral deformities (con-
sistent with fracture) were identified by direct visuali-
sation using the Genant semi-quantitative grading
scale [7,8]. Plain radiography was used except for some
patients who had computed tomography scans only.
S y n c h r o n o u sb o n em e t a s t a s i sw a sd e f i n e da ss i m u l t a -
neous diagnosis of prostate cancer and metastatic
spread to the bones. A p-value ≤ 0.05 was considered
statistically significant. No correction for multiple test-
ing was performed. The study was performed as a ret-
rospective analysis of skeletal complications. As a
quality of care analysis where data was fully de-identi-
fied, no approval from the Regional Committees for
Medical and Health Research Ethics (REK) was
necessary.
Results
The patient characteristics and length of follow-up are
shown in Table 1. Treatment consisted of different
types of androgen suppression regimens incl. steroids
and palliative external beam radiotherapy in patients
with bone pain, MSCC or surgically stabilized PF.
Administration of other treatments is also shown in
Table 1. Twenty-nine patients (48%) received taxotere
after diagnosis of bone metastases and 7 of these also
proceeded to second-line treatment with mitoxantrone.
The initial number of bone metastases on radioisotope
bone scan was significantly higher in patients with
synchronous presentation compared to metachronous
presentation, p = 0.05. Patients with synchronous pre-
sentation also had significantly higher median prostate-
specific antigen (PSA) value, p < 0.01, ALP value (p <
0.01) and LDH value (p = 0.03), as shown in Table 1.
No other significant differences in baseline characteris-
tics were found between these two groups, which did
not differ significantly in overall survival or development
of MSCC and PF.
Median actuarial survival after diagnosis of bone
metastases was 23 months. Six patients (10%) were alive
at 5 years. The parameters shown in Table 2 were
examined for their prognostic impact by comparing
actuarial survival curves (log rank test). While Hb at the
time of bone metastases detection was not significant
when using the median value as cut-off, a significant
association between Hb ≤ 12.0 g/dL and short survival
was found, p = 0.03. The 2-year survival rate in patients
with Hb ≤ 12.0 g/dL was 25%. Performance status also
was significant, p = 0.01. Patients with Eastern Coopera-
tive Oncology Group (ECOG) performance status of 2
had 33% 2-year survival, those with ECOG 1 43% and
t h o s ew i t hE C O G07 7 % .I nt h e s ea n a l y s e s ,a g e>7 0
years, ALP above median value, and LDH above median
value also predicted for significantly shorter survival, p ≤
0.05. A multivariate analysis confirmed performance sta-
tus, ALP and LDH as independent prognostic factors for
survival, p ≤ 0.05. Chemotherapy-treated patients had a
2-year survival rate of 65%. Patients managed without
chemotherapy because of age, poor performance status
and other contraindications had a 2-year survival rate of
39% (median survival 29 months with chemotherapy
versus 17 months without).
Eighty-nine percent of patients required external beam
radiotherapy and/or radioisotopes for bone metastases
treatment during follow-up. None of the patients had
disorders of calcium metabolism at diagnosis. No epi-
sodes of hypercalcemia developed during follow-up.
Seventeen patients (28%) developed at least one major
skeletal complication, i.e. MSCC or PF (4 of them devel-
oped more than one). As shown in Figure 1, 9 patients
suffered from MSCC and 8 from PF as first major com-
plication. Most events developed before treatment with
zoledronic acid and/or taxotere. In addition, 2 patients
were diagnosed with osteoporotic vertebral fractures
that were treated conservatively. These patients are not
included in the following actuarial analyses and explora-
tion of risk factors for major skeletal complications.
Median survival from diagnosis of either MSCC or PF
was 11 months, range 1-84. Median survival from diag-
nosis of MSCC was 5 months, range 1-63. Figure 2
shows the time to development of the first major skele-
tal complication. In this actuarial analysis, 44% of
patients had developed at least one major skeletal com-
plication at 4 and 5 years. We identified only two poten-
tial risk factors for development of major skeletal
complications, serum ALP above median value (p = 0.1)
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patients no statistical significance was obtained.
Discussion
The present study is to our best knowledge the only
community-based contemporary series examining the
incidence, outcome and risk factors for development of
major skeletal complications in patients treated for
bone metastases from prostate cancer. As the group
size and thus statistical power is limited, confirmatory
studies in larger databases should be attempted. Our
data are derived from a representative unselected
patient population, actually including all men with
bone metastases from prostate cancer in a well defined
geographical region. Data from the Cancer Registry of
Norway http://www.kreftregisteret.no have shown that
the age-adjusted prostate cancer incidence rate per
100,000 person years in Norway (96.6) is comparable
to that in our region (100.2) [9]. In Norway, treatment
recommendations are based on national guidelines.
Therefore, we have no reason to believe that our data
are flawed by serious selection bias. Nevertheless, ret-
rospective analyses should be interpreted cautiously.
Prospective evaluation might provide a better picture
of skeletal complications in patients with metastatic
prostate cancer.
Treatment was individualised, taking into account
age, organ function, performance status, symptoms, life
expectancy etc. Forty-eight percent of patients received
taxotere after diagnosis of bone metastases and some
Table 1 Patient characteristics
Parameter All 61 patients 23 patients with bone
metastases at first cancer
diagnosis
38 patients with metachronous
diagnosis of bone metastases
Median age, range (years)* 69, 56-86 67, 57-79 73, 56-86
Median age at first cancer diagnosis,
range (years)
68, 53-80 67, 57-79 68, 53-80
Median ECOG PS, range* 1, 0-2 1, 0-2 1, 0-2
Median interval, range (months) 22, 0-159 0 51, 5-159
Median PSA doubling time, range (months)* Not applicable Not applicable 2.5, 1-8
Median PSA, range (μg/L)* 49, 3.9-10,302 173, 12-10,302 23, 3.9-727
Median Hb, range (g/dL)* 13.7, 10.0-16.8 13.9, 10.0-16.8 13.4, 10.2-15.2
Median ALP, range (U/L)* 118, 44-2742 184, 56-2742 102, 44-641
Median LDH, range (U/L)* 206, 158-784 357, 190-784 196, 158-781
Hypo- or hypercalcemia* 0 0 0
Bone pain* 30 11 19
49% 48% 50%
Gleason score < 7, 7, >7** 6, 11, 27 2, 5, 11 4, 6, 16
14%, 25%, 61% 11%, 28%, 61% 15%, 23%, 62%
Other distant metastases* 19 8 11
31% 35% 29%
≤10 bone metastases, >10, 26, 29, 6 6, 12, 5 20, 17, 1
superscan 43%, 48%, 10% 26%, 52%, 22% 53%, 45%, 3%
Initial prostatectomy or radical 10 0 10
radiotherapy 16% 26%
Taxotere treatment 29 12 17
48% 52% 45%
Zoledronic acid treatment 44 18 26
72% 78% 68%
Radioisotope treatment 8 5 3
13% 22% 8%
Alive at the time of analysis 34 14 20
56% 61% 53%
Median follow-up of living patients,
range (months)
25, 6-84 29, 9-84 23, 6-67
* when diagnosed with bone metastases
** unknown in 5 patients with synchronous and 12 patients with metachronous diagnosis
ECOG PS: Eastern Cooperative Oncology Group performance status, PSA: prostate-specific antigen, Hb: haemoglobin, ALP: alkaline phosphatase, LDH: lactate
dehydrogenase
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trone. The 2-year survival rate was 65% in chemother-
apy-treated patients and 39% in others. This difference
is only partially attributable to treatment as this was a
retrospective study where several selection factors
influenced the choice of treatment. Median overall sur-
vival was 23 months. Established prognostic models
such as the one developed by Halabi et al., which
includes, e.g., performance status, Hb, ALP, LDH and
PSA, were derived from large databases [10]. With the
current number of patients, only the strongest prog-
nostic factors for survival could be identified. However,
these results are in line with the ones published by
Halabi et al. [10].
Forty-nine percent of patients had bone pain already
at baseline and 89% eventually required external beam
radiotherapy and/or radioisotopes during the course of
disease. In a recent Japanese study, the corresponding
figures were 45% and 51%, respectively [11]. In that
study, 14% of patients experienced bone fracture com-
pared to 13% in the present one. A study from the US
arrived at a rate of radiotherapy utilisation of 89% and
development of PF in 23% [12]. The threshold for radio-
therapy utilisation versus medical management of pain
Table 2 Prognostic factors for survival in all 61 patients
Parameter Unfavourable prognosis (comparison of actuarial
survival curves, log rank test)
Multivariate analysis (Cox
proportional hazards model)
Median age (years)* age > 70 years, p = 0.04 Not significant
Median age at first cancer diagnosis (years) Not significant
Median ECOG PS* Increasing ECOG PS, p = 0.01 Significant, p = 0.03
Median interval (months)** Not significant
Median PSA doubling time (months)** PSA doubling time < 3 months, p = 0.03 Not significant
Median PSA (μg/L)* Not significant
Hb (g/dL)* Hb ≤ 12.0 g/dL, p = 0.03 Not significant
Median ALP (U/L)* ALP > 118 U/L, p < 0.01 Significant, p = 0.02
Median LDH (U/L)* LDH > 206 U/L, p < 0.01 Significant, p = 0.03
Hypo- or hypercalcemia* Not significant
Bone pain* Not significant
Gleason score Not significant
Other distant metastases* Not significant
≤10 bone metastases, >10, superscan Not significant
ECOG PS: Eastern Cooperative Oncology Group performance status, PSA: prostate-specific antigen, Hb: haemoglobin, ALP: alkaline phosphatase, LDH: lactate
dehydrogenase
* when diagnosed with bone metastases
**only available in patients with metachronous diagnosis
Unselected population of 61 patients
9 patients (15%) with metastatic spinal cord 
compression (MSCC) as first event
- 2 presented with MSCC when bone metastases
were detected or within 2 months 
- 5 developed MSCC as they became castration-resistant 
(before start with zoledronic acid)
- 2 developed MSCC after failure of taxotere treatment but 
while on continued therapy with zoledronic acid
8 patients (13%) with pathologic fracture 
(PF) as first event
- 2 presented with PF when bone metastases were 
detected or within 2 months 
- 5 developed PF as they became castration-resistant 
(before start with zoledronic acid)
- 1 developed PF while on continued taxotere and 
zoledronic acid treatment
MSCC localisation and symptoms:
1 thoracocervical spine, 2 thoracolumbar spine, 6 thoracic spine only
2 one spinal element, 2 two spinal elements, 5 three or more elements
2 paraplegia and incontinence, 4 paraparesis, 3 slight motor deficit
Fracture localisation:
3 femur, 1 os pubis, 2 spine, 1 humerus, 1 clavicula 
1 patient developed PF (spine) later during follow-up 3 patients developed additional PF (spine) later during follow-up
Figure 1 Overview on development of major skeletal complications in 61 contemporary patients with bone metastases from prostate
cancer.
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introduces a possible source of bias when reporting ske-
letal-related events (SRE) and was the reason for focus-
ing the present study on major skeletal complications. It
should be noticed that androgen deprivation therapy
might result in bone loss and osteoporotic fractures
[13]. Depending on imaging modality, differentiation
between osteoporotic and metastatic fractures might be
challenging. In our own series, only 2 patients were
thought to have had osteoporotic fractures. When add-
ing these patients to the 9 with PF, the overall bone
fracture rate increased to 18%. Additional PF after the
first event developed in 3 patients. Most events occurred
before initiation of treatment with zoledronic acid and/
or taxotere, i.e. during the phase where patients devel-
oped castration-resistant disease. In some cases, PF led
to the diagnosis of prostate cancer. Berruti et al.
reported that 5% of all SRE developed before the onset
of castration-resistant disease [14]. Not all patients in
our series were treated with zoledronic acid. The main
reasons for withholding treatment were severe renal dys-
function and anticipated short survival, e.g., in patients
with considerable extraskeletal metastases unfit for che-
motherapy. Zoledronic acid significantly reduces the
skeletal morbidity rate [15]. Early treatment initiation in
patients at high risk of PF and other SRE might thus be
beneficial. We will later discuss the potential risk factors
for SRE, which includes a broader range of events, and
major skeletal complications, which we defined as
MSCC and PF. In a series of 68 surgically treated
patients with PF or impending fracture, median survival
from surgery was 1 year [16]. In our own series, all 8
patients with PF survived for more than 1 year (median
16 months).
MSCC developed in 15% of our patients. This rate is
slightly higher than in other studies. However, the defi-
nition of MSCC or impending MSCC is somewhat sub-
jective and varies from centre to centre. We did not
screen for MSCC in asymptomatic patients. Bayley et al.
reported that occult subarachnoid space or spinal cord
compression was diagnosed in 32% of patients examined
with magnetic resonance imaging [17]. Median survival
from diagnosis of MSCC was comparable to other series
[4]. As with PF, most MSCC events occurred before
initiation of treatment with zoledronic acid and/or taxo-
tere. Hypercalcemia, which was not observed in this ser-
ies, is a relatively rare event in prostate cancer patients
(8% in the study by Tucci et al. [18]). However, these
patients appear to have higher LDH values and bone
pain as well as a poor prognosis and higher risk to
develop SRE. Another important SRE risk factor is ALP
level, in this case bone ALP [3]. Baseline cross-linked N-
telopeptides of type I collagen (NTx) was also identified
as predictor of SRE [19]. That study was performed in
patients treated with zoledronic acid. A different study
found that SRE risk can be predicted by disease extent
i nb o n ea n dp a i ns c o r e[ 1 4 ] .O u ro w ns t u d yw a sh a m -
pered by the limited number of events. Even a broader
definition of SRE would have resulted in low statistical
power. It is nevertheless noticeable that serum ALP
level approached statistical significance. More specific
markers of bone turnover were not measured in our
patients. Presence of bone pain at baseline and extent of
spread on isotope bone scans was not associated with
increased risk. In the study by Smith et al., which looked
at bone ALP, this parameter was the most important
risk factor [3].
Conclusions
Bone pain, MSCC and PF continue to be common
events during the course of prostate cancer with skele-
tal metastases. Serious SRE contribute significantly to
morbidity and pose challenges to those involved in pal-
liative care for these patients. Prevention of skeletal
morbidity is a worthwhile goal in high-risk patients.
Candidate risk factors defining high-risk groups, e.g.,
ALP, NTx and hypercalcemia, need to be studied in
larger databases. Future studies might need to analyse
patients already receiving zoledronic acid and/or taxo-
tere separately from those continuing on endocrine
treatment alone.
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Figure 2 Kaplan-Meier estimate of time to development of first
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